Pioglitazone chemical structure
Find information on thousands of medical conditions and prescription drugs.

Actos

In medicine and pharmacology, pioglitazone is a member of the drug class of the thiazolidinediones.

It is being marketed as Actos® by the pharmaceutical companies Takeda and Eli Lilly.

Like other thiazolidinediones, its mechanism of action is by activation the intracellular receptor class of the peroxisome proliferator-activated receptors (PPARs), specifically PPARγ.

Side-effects and contraindications

See main article: thiazolidinedione
Home
Diseases
Medicines
A
8-Hour Bayer
Abacavir
Abamectin
Abarelix
Abciximab
Abelcet
Abilify
Abreva
Acamprosate
Acarbose
Accolate
Accoleit
Accupril
Accurbron
Accure
Accuretic
Accutane
Acebutolol
Aceclidine
Acepromazine
Acesulfame
Acetaminophen
Acetazolamide
Acetohexamide
Acetohexamide
Acetylcholine chloride
Acetylcysteine
Acetyldigitoxin
Aciclovir
Acihexal
Acilac
Aciphex
Acitretin
Actifed
Actigall
Actiq
Actisite
Actonel
Actos
Acular
Acyclovir
Adalat
Adapalene
Adderall
Adefovir
Adrafinil
Adriamycin
Adriamycin
Advicor
Advil
Aerobid
Aerolate
Afrinol
Aggrenox
Agomelatine
Agrylin
Airomir
Alanine
Alavert
Albendazole
Alcaine
Alclometasone
Aldomet
Aldosterone
Alesse
Aleve
Alfenta
Alfentanil
Alfuzosin
Alimta
Alkeran
Alkeran
Allegra
Allopurinol
Alora
Alosetron
Alpidem
Alprazolam
Altace
Alteplase
Alvircept sudotox
Amantadine
Amaryl
Ambien
Ambisome
Amfetamine
Amicar
Amifostine
Amikacin
Amiloride
Amineptine
Aminocaproic acid
Aminoglutethimide
Aminophenazone
Aminophylline
Amiodarone
Amisulpride
Amitraz
Amitriptyline
Amlodipine
Amobarbital
Amohexal
Amoxapine
Amoxicillin
Amoxil
Amphetamine
Amphotec
Amphotericin B
Ampicillin
Anafranil
Anagrelide
Anakinra
Anaprox
Anastrozole
Ancef
Android
Anexsia
Aniracetam
Antabuse
Antitussive
Antivert
Apidra
Apresoline
Aquaphyllin
Aquaphyllin
Aranesp
Aranesp
Arava
Arestin
Arestin
Argatroban
Argatroban
Argatroban
Argatroban
Arginine
Arginine
Aricept
Aricept
Arimidex
Arimidex
Aripiprazole
Aripiprazole
Arixtra
Arixtra
Artane
Artane
Artemether
Artemether
Artemisinin
Artemisinin
Artesunate
Artesunate
Arthrotec
Arthrotec
Asacol
Ascorbic acid
Asmalix
Aspartame
Aspartic acid
Aspirin
Astemizole
Atacand
Atarax
Atehexal
Atenolol
Ativan
Atorvastatin
Atosiban
Atovaquone
Atridox
Atropine
Atrovent
Augmentin
Aureomycin
Avandia
Avapro
Avinza
Avizafone
Avobenzone
Avodart
Axid
Axotal
Azacitidine
Azahexal
Azathioprine
Azelaic acid
Azimilide
Azithromycin
Azlocillin
Azmacort
Aztreonam
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Read more at Wikipedia.org


[List your site here Free!]


No Liver Toxicity Problems With Avandia, Actos - Brief Article
From Family Pratice News, 8/1/00 by Miriam E. Tucker

SAN ANTONIO -- Neither Avandia nor Actos, the two insulin-sensitizing diabetes drugs on the U.S. market, appear to share the liver toxicity problems of Rezulin, based on the results of two industry-sponsored studies presented at the annual scientific session of the American Diabetes Association.

Since Rezulin (troglitazone) was pulled from the U.S. market in March 2000 because of excess hepatotoxicity, there has been lingering concern that the problem could be a class effect common to all thiazolidinedione (TZD) agents or to other drugs that target the peroxisome proliferator-activated receptor-[gamma] (PPAR-[gamma]).

The issue is complicated by the fact that a small proportion of diabetics would be expected to develop some sort of liver disorder no matter what treatment they were on, said Dr. Harold E. Lebovitz, director of the diabetes diagnostic and treatment center at the State University of New York, Brooklyn.

In a recent study done in the United Kingdom, 1.5% of 40,190 type 2 diabetics who were taking non-TZD oral antidiabetic agents experienced elevated liver enzymes. Of those, 41% had preexisting liver abnormalities, 31% had only transient elevations, 19% had a specific nondrug cause (such as hepatitis), and only 10% of patients had a possible drug-induced elevation. "Postmarketing surveillance of any drug will find about a 5 per 1,000 rate of liver disease," said Dr. Lebovitz, who is a consultant for SmithKline Beecham Pharmaceuticals, Philadelphia.

As of November 1999, the rate of ALT levels that were three or more times the upper limit of normal has been 2.9 per 1,000 patient-years for rosiglitazone (Avandia), compared with 5.9 per 1,000 for placebo and 7.3 per 1,000 with suifonylureas or metformin. The difference is not statistically significant. Troglitazone's equivalent rate of liver enzyme elevation was three times greater.

Moreover, the Food and Drug Administration found that the rates of liver failure with troglitazone rose the longer it was on the market, from 16 cases by the end of the third quarter to 40 cases by the fifth. In contrast, there have only been two cases of liver failure among the more than one million people who have taken rosiglitazone, and the rate isn't increasing with time. Both of those patients were found to have other conditions predisposing them to liver failure, he noted.

"I think we can conclude that the hepatotoxicity with troglitazone is unique and is not a class effect of the TZDs or PPAR-[gamma]. These data should give us more confidence as we move ahead with the two drugs on the market and new drug development," Dr. Lebovitz remarked at the session.

The data for Actos (pioglitazone), presented in a poster by Dr. Cindy J. Rubin and Dr. Roberta L. Schneider of Takeda America Research and Development Center Inc., Princeton, N.J., were similarly reassuring.

During placebo-controlled U.S. trials, ALT levels of three or more times the upper limit of normal occurred in 4 of 1,526 patients on the drug and in 2 of 793 placebo-treated patients, a nearly identical result. Among all 2,561 patients in controlled and open-label U.S. trials of pioglitazone, 0.43% have experienced that degree of liver enzyme elevation. Of those, seven patients had elevated ALT levels prior to starting the drug treatment, two had other predisposing conditions, and one had no clearly associated event.

The elevated ALT levels were reversible in all of the patients for whom follow-up values were obtained, and none of the elevations was considered serious, Dr. Rubin and Dr. Schneider said.

COPYRIGHT 2000 International Medical News Group
COPYRIGHT 2001 Gale Group

Return to Actos
Home Contact Resources Exchange Links ebay